The ENDEAR Trial of Nusinersen in Infantile-Onset SMA
Basil Darras, MD reviews data from the ENDEAR trial of nusinersen in infantile SMA and discusses the agent’s safety and efficacy in patients of differing age groups as studied in other trials.
The Evolving Therapeutic Landscape for SMA
Carolina Tesi Rocha, MD examines the recent shift to disease-modifying treatment in SMA, and the panel reviews factors to consider when tailoring therapy to individual patients.
The Importance of ALS Awareness Month: Matthew B. Harms, MD
May 6th 2021The associate professor of neurology at Columbia University and medical consultant and care center director, Muscular Dystrophy Association, discusses the impact that the Ice Bucket Challenge and ALS Awareness Month have had on the ALS treatment landscape.
Multidisciplinary Approach to Palliative Care in ALS
Expert neurologists discuss the importance of a multidisciplinary approach to the management of symptoms for palliative care in amyotrophic lateral sclerosis (ALS).
Diagnosis and Management of ALS During COVID-19
A panel of key opinion leaders provides insight into how COVID-19 has continued to impact the diagnosis and management of patients with amyotrophic lateral sclerosis (ALS).
Counseling Patients On High-Efficacy Therapy for RRMS
May 3rd 2021Robert Fox, MD, of the Cleveland Clinic, comments on the advantage of starting treatment with a high-efficacy therapy for relapsing-remitting multiple sclerosis and explains his approach to counseling patients when selecting treatment.
Treating RRMS: Low Vs High-Efficacy Therapy
May 3rd 2021Dr Patricia K. Coyle, of the Stony Brook Neurosciences Institute, comments on her approach to selecting first-line therapy to treat relapsing-remitting multiple sclerosis, explaining how she selects between a lower-risk or high-efficacy therapy.
AUPN Leadership Minute Episode 10: What Your CEO Wants From You
May 1st 2021Episode 10 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and Albert L. Wright, Jr., the president and CEO of West Virginia University Health System. [WATCH TIME: 4 minutes]